HEREDITARY PANCREATIC CANCER

Hereditary Pancreatic Cancer — approximately 10% of pancreatic cancers have a genetic cause, and screening programs for confirmed carriers detect tumors at resectable stages where 5-year survival exceeds 40%, compared to <12% when detected symptomatically.

Whole genome sequencing evaluates all pancreatic cancer predisposition genes — BRCA2, PALB2, ATM, CDKN2A, STK11, MLH1, MSH2, and others — identifying individuals who qualify for pancreatic cancer screening programs that save lives through early detection.

BRCA2
PALB2
ATM
CDKN2A
STK11
MLH1
MSH2

About this condition

Pancreatic Cancer — Hereditary

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers — approximately 64,000 new US cases annually with overall 5-year survival of ~12%. The poor prognosis is primarily due to late-stage detection: >80% of cases are diagnosed at unresectable stages because early-stage PDAC is asymptomatic. However, approximately 5-10% of pancreatic cancers have a hereditary component with identifiable germline pathogenic variants in BRCA2 (~3-5% of PDAC, 3-10x risk), PALB2 (2-6x risk), ATM (2-5x risk), CDKN2A/p16 (13-22x risk), STK11/Peutz-Jeghers (132x risk), and Lynch syndrome genes MLH1/MSH2 (9x risk).

The International Cancer of the Pancreas Screening (CAPS) consortium recommends annual pancreatic screening with MRI and/or endoscopic ultrasound (EUS) for individuals with pathogenic variants in high-risk genes (BRCA2, PALB2, ATM, CDKN2A, STK11, MLH1/MSH2) starting at age 50 (or 10 years before the youngest family case). Screening programs detecting CAPS-qualifying lesions achieve resection rates >60% and stage I detection in ~60-80% — compared to <20% stage I at symptomatic diagnosis. This stage shift translates directly to improved survival.

Beyond screening, germline genetic testing has therapeutic implications for pancreatic cancer treatment. BRCA2 and PALB2 pathogenic variants confer sensitivity to platinum-based chemotherapy (FOLFIRINIX) and PARP inhibitors — olaparib maintenance therapy is FDA-approved for germline BRCA-mutated metastatic pancreatic cancer. ATM deficiency may confer sensitivity to PARP inhibitors and ATR inhibitors in clinical trials. These gene-specific treatment responses make germline testing relevant for all pancreatic cancer patients, not just those with family history.

CDKN2A/p16 carriers have 13-22x pancreatic cancer risk — the highest of any non-syndromic gene. Yet CDKN2A is primarily known as a melanoma gene. Any family with both melanoma AND pancreatic cancer should have CDKN2A testing urgently.

Gene locus: BRCA2 (13q13.1), PALB2 (16p12.2), ATM (11q22.3), CDKN2A (9p21.3), STK11 (19p13.3), MLH1 (3p21.3), MSH2 (2p21)

Pancreatic cancer screening saves lives when targeted to genetically confirmed high-risk individuals. Without molecular testing, these individuals remain unidentified until symptomatic — when 80% of tumors are already unresectable.

Olaparib maintenance is FDA-approved for germline BRCA-mutated metastatic pancreatic cancer — molecular testing determines eligibility

The POLO trial demonstrated that olaparib maintenance therapy significantly improved progression-free survival in germline BRCA1/2-mutated metastatic PDAC. NCCN guidelines now recommend germline genetic testing for ALL pancreatic cancer patients — not just those with family history — because approximately 5-10% carry actionable germline variants. Without molecular testing, patients with BRCA-mutated pancreatic cancer receive standard chemotherapy alone, missing the PARP inhibitor maintenance that could extend their lives.

Pancreatic screening with MRI/EUS detects cancer at resectable stages — but enrollment requires confirmed genetic high-risk status

Pancreatic cancer screening is not recommended for the general population (low prevalence, imperfect specificity). It IS recommended for individuals with confirmed germline high-risk variants — where the pre-test probability is high enough to make screening cost-effective and clinically beneficial. CAPS consortium enrollment requires documented pathogenic variant in a qualifying gene. WGS identifies all qualifying genes from a single test, enabling immediate screening enrollment that catches tumors when surgery is still curative.

Hereditary Pancreatic Cancer — approximately 10% of pancreatic cancers have a genetic cause, and screening programs for confirmed carriers detect tumors at resectable stages where 5-year survival exceeds 40%, compared to <12% when detected symptomatically.

Pancreatic Cancer — Hereditary

Pancreatic cancer screening saves lives when targeted to genetically confirmed high-risk individuals. Without molecular testing, these individuals remain unidentified until symptomatic — when 80% of tumors are already unresectable.

Olaparib maintenance is FDA-approved for germline BRCA-mutated metastatic pancreatic cancer — molecular testing determines eligibility

Pancreatic screening with MRI/EUS detects cancer at resectable stages — but enrollment requires confirmed genetic high-risk status

Others in Hereditary Cancer

One test. A lifetime of answers.